Hypothalamic Neurokinin B Receptor Antagonism: A Novel Approach to Menopausal Hot Flashes?

Small, randomized trial suggests the potential of this pharmacologic strategy.

Over 70% of menopausal women experience bothersome hot flashes that can persist for years. Although estrogen is the most effective therapy, associated risks can make it unsuitable for some. Recent data have implicated hypothalamic neurokinin B (NKB) and its receptor, NK3R, in the etiology of hot flashes; hence, investigators conducted a manufacturer-supported randomized crossover trial to determine if pharmacologic blockade of NK3R with an orally active antagonist (MLE4901) might represent an effective, novel approach to managing menopausal hot flashes. Thirty-seven healthy postmenopausal women (age range, 40–62) with ≥7 hot flashes daily received 4 weeks of MLE4901 (40 mg orally twice daily) or identical placebo followed by a 2-week washou…

Reviewing Author

Robert W. Rebar, MD

Disclosures

Consultant/Advisory BoardMyovant Sciences, Inc.

Editorial BoardsEndoText; Clinical OB/GYN Alert

Leadership Positions in Professional SocietiesAmerican Society for Reproductive Medicine (Member, Ethics Committee)

Robert W. Rebar, MD

Disclosures

Consultant/Advisory BoardMyovant Sciences, Inc.

Editorial BoardsEndoText; Clinical OB/GYN Alert

Leadership Positions in Professional SocietiesAmerican Society for Reproductive Medicine (Member, Ethics Committee)

Hypothalamic Neurokinin B Receptor Antagonism: A Novel Approach to Menopausal Hot Flashes?

Topics

Reviewing Author